Effectiveness of recombinant hepatitis B vaccine

ABSTRACT

The study was carried out to see the efficacy of recombinant hepatitis B vaccine [Engerix 'B' by SK and F] in two high risk groups viz; chronic renal failure patients on maintenance haemodialysis [n=20] and medical staff [n-25]. The prevaccination status of these individuals was assessed by HB[s]A[g], Anti-HB[s] and LFT[s]. Only those subjects were included in this study who were negative for HB[s]A[g] and Anti-HB[s]. The patients were given 2cc while the staff 1cc dose of the vaccine intramuscularly at the schedule of 0, 1 and 6 months. Quantitative estimation of antibody titre [seroconversion] was noted by ELISA method 15 days after the last dose. This become positive in 84% of the medical staff members and 65% of the patients in a concentration of >/= 10IU/L